Antitumor agents. 120. New 4-substituted benzylamine and benzyl ether derivatives of 4'-O-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II. 1991

X M Zhou, and Z Q Wang, and J Y Chang, and H X Chen, and Y C Cheng, and K H Lee
Natural Products Laboratory, University of North Carolina, Chapel Hill 27599.

A number of new 4'-O-demethylepipodophyllotoxin derivatives possessing various 4 beta-N- or 4 beta-O-benzyl groups have been synthesized and evaluated for their inhibitory activity against the human DNA topoisomerase II as well as for their activity in causing cellular protein-linked DNA breakage. The 4 beta-N-benzyl derivatives 9-22 are, in general, as active or more active than etoposide (1). The most active compounds are 14, 16, and 17, which are more than 2-fold more potent than 1. The results indicated that a basic unsubstituted 4 beta-benzylamino moiety is structurally required for the enhanced activity. Replacement of the benzyl nitrogen with oxygen gave compounds (23 and 24) which are inactive. The ability of these compounds to inhibit human DNA topoisomerase II and to cause protein-linked DNA breakage appears to have no direct correlation with cytotoxicity in KB cells.

UI MeSH Term Description Entries
D011034 Podophyllotoxin A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. Epipodophyllotoxin,CPH86,Condyline,Condylox,Podocon-25,Podofilm,Podofilox,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-Isomer,Wartec,Warticon
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D059005 Topoisomerase II Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. DNA Gyrase Inhibitor,DNA Topoisomerase II Inhibitor,Topoisomerase 2 Inhibitors,Topoisomerase II Inhibitor,DNA Gyrase Inhibitors,DNA Topoisomerase II Inhibitors,DNA Type 2 Topoisomerase Inhibitors,Gyrase Inhibitor, DNA,Gyrase Inhibitors, DNA,II Inhibitor, Topoisomerase,Inhibitor, DNA Gyrase,Inhibitor, Topoisomerase II,Inhibitors, DNA Gyrase,Inhibitors, Topoisomerase 2,Inhibitors, Topoisomerase II

Related Publications

X M Zhou, and Z Q Wang, and J Y Chang, and H X Chen, and Y C Cheng, and K H Lee
September 1990, Journal of medicinal chemistry,
X M Zhou, and Z Q Wang, and J Y Chang, and H X Chen, and Y C Cheng, and K H Lee
May 1990, Journal of medicinal chemistry,
X M Zhou, and Z Q Wang, and J Y Chang, and H X Chen, and Y C Cheng, and K H Lee
March 1993, Pharmaceutical research,
X M Zhou, and Z Q Wang, and J Y Chang, and H X Chen, and Y C Cheng, and K H Lee
August 1992, Journal of natural products,
X M Zhou, and Z Q Wang, and J Y Chang, and H X Chen, and Y C Cheng, and K H Lee
December 2022, European journal of medicinal chemistry,
X M Zhou, and Z Q Wang, and J Y Chang, and H X Chen, and Y C Cheng, and K H Lee
January 1989, Journal of natural products,
X M Zhou, and Z Q Wang, and J Y Chang, and H X Chen, and Y C Cheng, and K H Lee
August 2022, Molecules (Basel, Switzerland),
X M Zhou, and Z Q Wang, and J Y Chang, and H X Chen, and Y C Cheng, and K H Lee
June 2004, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!